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Abstract
Background: XELOX (capecitabine + oxaliplatin) and FOLFOX 4 (5-FU + folinic acid + oxaliplatin) have shown
similar improvements in survival in patients with metastatic colorectal cancer (MCRC). A US cost-minimization study
found that the two regimens had similar costs from a healthcare provider perspective but XELOX had lower costs
than FOLFOX4 from a societal perspective, while a Japanese cost-effectiveness study found XELOX had superior
cost-effectiveness. This study compared the costs of XELOX and FOLFOX4 in patients with MCRC recently treated
in two oncology departments in Hong Kong.
Methods: Cost data were collected from the medical records of 60 consecutive patients (30 received XELOX and
30 FOLFOX4) from two hospitals. Drug costs, outpatient visits, hospital days and investigations were recorded and
expressed as cost per patient from the healthcare provider perspective. Estimated travel and time costs were
included in a societal perspective analysis. All costs were classed as either scheduled (associated with planned
chemotherapy and follow-up) or unscheduled (unplanned visits or admissions and associated tests and medicines).
Costs were based on government and hospital sources and expressed in US dollars (US$).
Results: XELOX patients received an average of 7.3 chemotherapy cycles (of the 8 planned cycles) and FOLFOX4
patients received 9.2 cycles (of the 12 planned cycles). The scheduled cost per patient per cycle was $2,046 for XELOX
and $2,152 for FOLFOX4, while the unscheduled cost was $240 and $421, respectively. Total treatment cost per patient
was $16,609 for XELOX and $23,672 for FOLFOX4; the total cost for FOLFOX4 was 37% greater than that of XELOX. The
addition of the societal costs increased the total treatment cost per patient to $17,836 for XELOX and $27,455 for
FOLFOX4. Sensitivity analyses showed XELOX was still less costly than FOLFOX4 when using full drug regimen costs,
incorporating data from a US model with costs and adverse event data from their clinical trial and with the removal of
oxaliplatin from both treatment arms. Capecitabine would have to cost around four times its present price in Hong
Kong for the total resource cost of treatment with XELOX to equal that of FOLFOX4.
Conclusion: XELOX costs less than FOLFOX4 for this patient group with MCRC from both the healthcare provider
and societal perspectives.
Background
Increasing healthcare expenditure is a universal problem
facing the developed world. In 2008, Australia’s health-
care expenditure reached AUS$104 billion (8.5% of
GDP) [1] and that of the United States (US) US$2.3 tril-
lion (16% of GDP) [2]. Expenditure on drugs has
recently been the fastest growing component of
expenditure in Australia [1], Canada [3,4], UK [5] and
US [6,7]. Whilst new treatments usually have a higher
purchase price than older, possibly off-patent drugs,
they may be a more efficient treatment when the full
costs and consequences are taken into account. This is
particularly the case with new, targeted therapies in
oncology, which often have high drug-acquisition costs
[8-10]. Cost-effectiveness analyses (CEA) are therefore
increasingly used by decision-makers to determine
which drugs should be included in public formularies
[1,3-7,11-17]. The UK National Institute of Health and
* Correspondence: smmcghee@hkucc.hku.hk
1Department of Community Medicine, School of Public Health, The
University of Hong Kong, Hong Kong
Full list of author information is available at the end of the article
Tse et al. BMC Cancer 2011, 11:288
http://www.biomedcentral.com/1471-2407/11/288
© 2011 Tse et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Clinical Excellence has used CEA since 1999 [14,18],
Australian Pharmaceutical Benefits Advisory Committee
since 1993 [14,19] and Canadian Common Drug Review
since 2002 [14,20]. In Hong Kong, the Hospital Author-
ity (HA) is a government-funded provider of specialist
healthcare services. Its Drug Advisory Committee
appraises new drugs for inclusion into the HA Drug
Formulary but has not, to date, required cost-effective-
ness evidence as a component of drug evaluation
[21,22]. This is a common situation for smaller coun-
tries or those, for example, in the Asia Pacific region
where skills in health economics are lacking [22,23] and
for which the available cost-effectiveness information,
derived from other countries, may or may not be applic-
able [22,24,25].
In this paper we demonstrate how the lack of cost-
effectiveness information could mask the cost implica-
tions of treatment decisions. The two treatments com-
pared were available for use in Hong Kong in the
treatment of metastatic colorectal cancer (MCRC) but
one (capcetabine + oxaliplatin) was totally self-financed
by the patient while the other had two components (5-
FU + folinic acid) subsidised by the HA although the
other component (oxaliplatin) was self-financed. By
examining local data on costs, we were able to demon-
strate that the current reimbursement procedures are
probably not the most efficient choice for the HA.
Methods
The treatments compared
In improving survival of patients with MCRC, XELOX
(capecitabine + oxaliplatin) has been shown in several
trials to be as effective as FOLFOX4 (5-FU + folinic acid
+ oxaliplatin) [26-28]. Economic models taking a provi-
der’s perspective have showed XELOX to be more cost-
effective than FOLFOX4 in Japan [29] but of equivalent
cost-effectiveness in US [30]. However, the US model
demonstrated cost-effectiveness of XELOX when a soci-
etal perspective, including patient costs and lost produc-
tivity, was taken.
The economic model
Cost-effectiveness analysis estimates a cost per unit of
benefit for alternative treatments so a treatment which
provides more benefit at the same cost or the same ben-
efit at lower cost would be more efficient. However, if
two treatments provide identical benefits, then the one
which costs least is more efficient. Since the clinical
trials had shown that XELOX was at least as effective as
FOLFOX4, [26-28] we focused on the costs of the two
treatments to determine the relative efficiency in Hong
Kong, assuming that the clinical effects would be the
same as in the US studies. While it is usual to accept
data on effectiveness as being applicable to a new
population, the same cannot be done with costs and
resource use which are likely to vary because of local
prices, values, treatment protocols and health care
practices.
The patients sampled
Patients with previously untreated MCRC who received
either XELOX or FOLFOX4 in two large general hospi-
tals (Queen Mary Hospital and Pamela Youde Nether-
sole Eastern Hospital) in Hong Kong were
retrospectively identified from the records of the oncol-
ogy departments. The predefined earliest treatment start
date was January 2003 to ensure comparability of other
factors and we aimed for thirty patients to be identified
retrospectively as undergoing each treatment. In practice
the earliest start date was January 2004 and the latest
was December 2008. Information on all use of public
hospital inpatient or outpatient resources was collected
from the medical records by experienced researchers for
up to 28 days after the end of chemotherapy treatment.
This included hospital days, all outpatient visits and
associated investigations and treatments. Patients’ base-
line demographics and clinical characteristics were com-
pared across both groups using a t-test for means and
the Kruskal-Wallis rank test for frequencies.
Identification, measurement and valuation of cost data
Monetary values of health care resources used were
taken from the Hong Kong Government Gazette, the
official source for charges to non-entitled persons for
use of public hospital services i.e. a cost-recovery charge.
The Gazette dates from 2003 but had not been updated
since then and so applied in 2009. Hong Kong citizens
are charged only a small co-payment for public inpatient
and outpatient services with the exception of drugs
which fall outside of the drug formulary which can be
prescribed on a self financed basis. The costs of capeci-
tabine and oxaliplatin for those on the XELOX regimen
and oxaliplatin for those on the FOLFOX4 regimen
were borne by patients because these drugs are not in
the formulary [31]. All costs have been reported in US$
(1US$ = 7.78HK$) to the nearest $ and 2009 is used as
the base year for costing.
In order to identify differences in resource use for
treatment and that for possible adverse events, all
resources used were separated into scheduled (defined
as incurred for chemotherapy delivery or standard fol-
low-up) and non-scheduled. Non-scheduled costs would
include any other costs such as treatment for adverse
events, disease progression or costs unrelated to the
chemotherapy.
From the information in the medical records, a hospi-
tal stay for chemotherapy delivery of 1 day for XELOX
and 3 days for FOLFOX4 was normal. Any further days
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Each hospital day was valued using the average bed-day
cost of $424 [32]. However, in order not to overestimate
the cost of the hospital days used for chemotherapy, the
single hospital day used for XELOX was valued at $180,
which is the listed cost of a one-day admission in a
community hospital plus an intravenous administration
of drugs [32]. For FOLFOX4, the 3 days for chemother-
apy were valued as the cost for two days or overnight
s t a y si . e .$ 8 4 8 .T h i sg a v eac o n s e r v a t i v ee s t i m a t ef o r
FOLFOX4 and a probably realistic estimate for XELOX.
Outpatient visits were valued using the average cost of
a specialist visit ($77), a GP visit ($26) or a visit to an
Accident and Emergency Department ($73) [32]. All
investigations and treatments were valued using the
standard costs for each [33]. All drugs were costed
using the standard drug costs in 2009 [34] and categor-
ized as chemotherapy regimens or non-chemotherapy
drugs.
Societal costs
Travel and time costs were estimated as this information
was not recorded in the medical records. Outpatient vis-
its were assumed to take 2 hours per visit including tra-
vel and were valued at $5 per hour based on the median
monthly salary [35]. Travel costs were based on the
actual distance between the patient’sh o m ea d d r e s sa n d
the hospital and the taxi fare for that distance [36] giv-
ing an average round-trip value of $14 for the XELOX
group and $12 for the FOLFOX4 group. Time costs
were also applied to the time spent in hospital assuming
that the day admission for XELOX took 6 hours and for
FOLFOX4 took 2 days (48 hours). For unscheduled hos-
pital visits, the average number of days was multiplied
by 24 hours to generate the average number of hospital
hours and travel costs were valued as for outpatient
visits.
To estimate a confidence interval for the total costs of
the two drug regimens, we carried out a bootstrap pro-
cedure with 1,000 replications, sampling with replace-
ment from the original data.
Sensitivity analysis
Sensitivity analyses were performed to evaluate the
impact of (a) using the costs of a full dose of each che-
motherapy drug based on the average body surface area
of 1.65 m
2 rather than the actual, lower dose recorded
in the records and the full number of cycles as per the
protocol i.e. 8 cycles for XELOX and 12 for FOLFOX4;
(b) with the cost of oxaliplatin removed because it is an
expensive, self-financed part of both chemotherapy regi-
mens and (c) using a US model developed in Excel by
Garrison et al [30] into which the Hong Kong unit costs
were inserted using an exchange rate of HK$7.78 to US
$1. This US model compared the scheduled costs of
XELOX versus FOLFOX4 arms in a non-inferiority
study which found XELOX to be at least as effective as
FOLFOX4. The study was conducted in a US setting
from both payer and societal perspectives and included
resource use, frequency and treatment of adverse events.
Although all unit costs used were based on Hong Kong
data, the frequency of adverse events and loss of work-
ing time were based on the US study.
Finally, in order to determine the sensitivity of the
results to the cost of capecitabine, we varied the average
chemotherapy cost for the XELOX group until the total
costs were the same for the XELOX and FOLFOX4
groups.
Ethics approval for the study was obtained from the
Institutional Review Board of both hospitals.
Results
Patients’ baseline characteristics
The baseline characteristics of patients receiving XELOX
and FOLFOX4 are shown in Table 1. There were no
statistically significant differences in the recorded char-
acteristics except that those in the XELOX group were
more likely to have had liver metastases at baseline.
Planned and actual dose
The average number of cycles of chemotherapy deliv-
ered was 7.3 out of a planned 8 cycles for XELOX and
9.2 out of a planned 12 cycles for FOLFOX4. Overall,
91% of the planned amount of capecitabine and 89% of
oxaliplatin was administered to the XELOX patients
while 77% of the planned amount of 5-FU, folinic acid
and oxaliplatin was administered to the FOLFOX4
patients.
Healthcare use
The average follow-up period, including the chemother-
apy treatment and up to 28 days post-treatment, was
199 and 168 days for the XELOX and FOLFOX4 groups
respectively. The healthcare use in the XELOX and
FOLFOX4 chemotherapy groups within the follow-up
period is shown in Table 2. The average number of hos-
pital days for chemotherapy in the FOLFOX4 group was
more than three times that of the XELOX group (33.2
vs. 10.3 days). The total cost per patient was higher for
the FOLFOX4 group compared with the XELOX group
both for the scheduled costs (chemotherapy plus
expected hospital days for its administration and sched-
uled clinic visits) and for the unscheduled costs (Table
3). Hence, in this analysis FOLFOX4 was 43% more
expensive than XELOX. The bootstrapped mean total
costs and 95% confidence interval were $16,410(95%CI:
$14,976-18,019) for XELOX and $22,169 (95%CI:
$20,010-24,315) for FOLFOX4.
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and unrelated adverse events (AE) would be captured as
unscheduled costs. The most common AE observed in
both groups was nausea; the most common AE in the
FOLFOX4 group was neutropenia followed by thrombo-
cytopenia and mild diarrhoea whilst the most common
A Ei nt h eX E L O Xg r o u pw a sm i l dh a n df o o ts y n d r o m e
followed by mild peripheral neuropathy and
thrombocytopenia.
Societal perspective
The scheduled patient time cost for XELOX was $51
per cycle with the unscheduled time cost $59. Scheduled
and unscheduled travel costs were $42 and $17 per cycle
respectively giving a total societal cost per patient for
XELOX of $17,836 (Table 4). For FOLFOX4, the sched-
uled patient time costs were $265 per cycle and the
unscheduled costs $99 while scheduled and unscheduled
travel costs were $33 and $14 per cycle respectively.
This gave a total treatment cost per patient for
FOLFOX4 from a societal perspective of $27,455 (Table
4). Thus, the inclusion of societal costs further increased
the cost difference between the two drugs with FOL-
FOX4 now being 54% more expensive than XELOX.
Sensitivity analysis
Full dosage based on the average body surface area
would cost $1,367 for XELOX and $751 for FOLFOX4







Male, % 57 57
Chinese ethnicity, % 94 100
Mean age, years 63.9 61.9 0.936*
Mean weight, kg 61.6 59.8 0.544*
Mean height, cm 165.4 162.6 0.281*
Mean body surface area, m
2 1.65 1.62 0.555*
ECOG PS, % of patients 0 34 30 0.860
‡
15 3 5 3
24 4
Alkaline phosphatase, % abnormal 20 17 0.741
‡
No. of metastatic sites, % of patients 1 57 53 0.822
‡
23 3 3 7
≥31 0 1 0
Liver metastases present, % of patients 77 50 0.034
‡
Status at August 2009, % surviving 67 47 0.121
‡
* T-test,
‡ Kruskal-Wallis rank test.










Chemotherapy cycles 7.3 (1.4) 9.2 (2.8)
Other drugs 9.3 (5.8) 12.4 (7.2)
Hospital bed-days 10.3 (5.2) 33.2 (9.1)
Outpatient clinic visits 15.5 (3.4) 16.5 (5.1)
Laboratory
investigations
38.6 (11.2) 37.3 (12.8)
X-rays and scans 4.3 (3.1) 3.8 (2.5)
Table 3 Comparative costs (US$) for first-line treatment








Scheduled costs per cycle
Chemotherapy cost 1,184 (152) 724 (84)
Hospital days for chemotherapy delivery 180 (-)* 848 (-)*
Hospital tests 55 (106) 76 (163)
Outpatient visits 155 (52) 135 (46)
Outpatient tests at scheduled visits 472 (291) 368 (191)
Total scheduled cost per cycle 2,046 (325) 2,152 (307)
Total scheduled cost per patient 14,866 (3,823) 19,801 (5,405)
Other unscheduled costs
Drug costs 4 (7) 44 (191)
Hospital days 201 (355) 355 (670)
Outpatient visits 15 (21) 13 (39)
Outpatient tests at unscheduled visits 20 (53) 9 (28)
Total unscheduled cost per cycle 240 (364) 421 (890)
Total unscheduled cost per patient 1,743 (2,197) 3,871 (3,870)
Total cost per patient 16,609 (4,710) 23,672 (5,904)
* These are estimated rather than measured (see methods) therefore no SD is
calculated.
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had been administered, total costs per patient would
become $19,753 for XELOX and $31,200 for FOLFOX4
i.e. FOLFOX4 was 58% more expensive than XELOX.
Removal of oxaliplatin from the analysis did not
impact on the cost difference from a healthcare payer
perspective since FOLFOX4 was now 69% more expen-
sive than XELOX.
XELOX was cost-effective in the US from a societal
perspective but not from a payer perspective [30]; how-
ever, using the same model with cost data from Hong
Kong showed XELOX to be cost-effective from both
payer and societal perspectives.
For the total average cost in the XELOX group to
equal that in the FOLFOX4 group, the average cost of
the capecitabine component of the chemotherapy would
have to be around $1,090 i.e. over four times the $213
found in the study.
Discussion
The XELOX regimen comprising capecitabine and oxali-
platin requires less intravenous administration than
FOLFOX4, comprising 5-FU, folinic acid and oxaliplatin.
Therefore it might be expected that it would cost less
overall when costs of drug delivery are taken into
account. This study showed that this was indeed the
case and that, when the fewer cycles of therapy required
with XELOX (8 versus 12) were also taken into account,
the savings in other costs outweighed the higher pur-
chase price of the XELOX regimen. However, the pub-
licly funded provider in HK subsidised the use of
FOLFOX4 and not XELOX, thus encouraging the use of
a regimen that resulted in higher use of hospital
resources. Those patients willing to bear the cost of the
alternative therapy because of the benefits they per-
ceived to themselves were saving resource costs for the
provider. This is, of course, because historically FOL-
FOX4 has been the approved treatment and XELOX,
the newer treatment, had a higher purchase price per
dose and had not yet been considered for inclusion into
the list of approved drugs for subsidy.
This cost analysis was a relatively simple study
designed to obtain information to allow a more consid-
ered assessment of the two regimens. Therefore, it must
be asked whether the information collected is adequate
for decision-making. Cost minimisation analysis (CMA)
i sd e f i n e db yD r u m m o n de ta l[ 3 7 ]a sad e s i g nu s e d
where the consequences are the same with a disparity in
costs only and it is relatively low cost, simple and quick
to conduct. This is an advantage for countries which
have few people with economic modelling skills. How-
ever, it depends on the major assumption that the clini-
cal effects of the comparison treatments are the same.
Such a finding of similar effectiveness is often extrapo-
lated from ‘negative’ trials, i.e. where neither drug is
found to be superior but these studies may have insuffi-
cient power to test equivalence of effects [38]. In the
case of these two drugs, there was some evidence from
trials designed to determine that the new drug was not
inferior to the alternatives [26-28] but we did not sub-
ject that evidence to a full review. One concern, when
the benefits have not been included in the economic
modelling, is that any negative impacts of the drugs may
not have been fully accounted for [35]. Therefore in a
costing study such as this one, it would be important to
consider what negative outcomes might occur in the
particular clinical situation and to consider doing a full
cost-effectiveness study if there should be any doubts.
For example, with a treatment such as XELOX which is
t a k e no na no u t p a t i e n tb a s i s ,w em i g h tb ec o n c e r n e d
that reduced frequency of contact with the doctor could
delay identification of side effects. Careful monitoring of
the patients or specific patient advice plus a contact
number to call might help to resolve this question.
A cost analysis is highly dependent on good local data
on costs and sufficiently completed medical records
from which resource use can be extracted. Hong Kong
has a computerised clinical information system which
covers all public medical services; cross-referencing was
conducted in this study between different sections of
the record to ensure completeness of the data captured.
We did not apply any discounting in this study
because the time course for each patient was less than a
year. All costs relate to the base year of 2009 even
though the actual resource use was in the years between
2004 and 2008.
Table 4 Comparative costs (US$) for first-line treatment








Scheduled costs per cycle
Treatment cost 2,046 (325) 2,152 (307)
Patient time cost 51 (-)* 265(-)*
Patient travel cost 42 (-)* 33 (-)*
Total scheduled cost per cycle 2,139 2,450
Total scheduled cost per patient 15,544 22,539
Other unscheduled costs
Treatment cost 240 (364) 421 (890)
Patient time cost 59 (-)* 99 (-)*
Patient travel cost 17 (-)* 14 (-)*
Total unscheduled cost per cycle 315 534
Total unscheduled cost per patient 2,292 4,915
Total cost per patient 17,836 27,455
* These are estimated rather than measured (see methods) therefore no SD is
calculated.
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higher purchase price than FOLFOX4, from the provi-
der’s perspective it could be a more cost-effective option
in Hong Kong since the total cost of its use was 70% of
that of FOLFOX4 when all healthcare resource use was
taken into account. This was mainly because of the
reduced need for hospital-based intravenous drug deliv-
ery, a finding that is consistent with Garrison et al [30]
and Scheithauer et al [39] in comparisons of the same
two drug regimens, as well as Perrocheau et al [40]
when comparing XELOX against FOLFOX6.
The finding of lower cost for XELOX differs from the
US results where the XELOX regimen was more expen-
sive than FOLFOX4. This is mainly the result of capeci-
tabine being approximately 8 times the cost of 5-FU in
US while in Hong Kong it was just over twice the price.
Our sensitivity analysis also showed that capecitabine
would have to be four times as expensive for the total
resource cost in the XELOX group to equal that in the
FOLFOX group.
The relative differences in other costs also combine to
make XELOX less costly even when the US data on
side-effects and subsequent resource use were modelled
together with Hong Kong costs. Taking a societal per-
spective increased the cost difference between XELOX
and FOLFOX4 as also found in the US [30]. This study
demonstrates the fact that cost-effectiveness evidence
cannot be easily generalised across jurisdictions
[22-25,41-43] and that local cost data are required.
We estimated the total costs of the treatment regi-
mens and this should now provide very useful informa-
tion for the healthcare providers to determine the
impact on their budgets of using one drug rather than
the other. Of course, the total costs of a treatment may
be spread across different budgets, for example a drug
procurement budget and a hospital bed provision bud-
get, including staffing, testing and other items. While
there may be higher costs in one budget e.g. drug pro-
curement this might be more than compensated for by
decreases in another. We hope that the information pro-
vided would allow such specific budget impacts to be
estimated. We also hope that our study will encourage
decision makers to take a more comprehensive view of
costs which might encompass more than one budget,
rather than focussing solely on the price of the drug.
Limitations of This Paper
Our study was a retrospective and non-randomised
study. It reflects the actual resource use of the subjects’
care but, of course, is subject to bias. Allocation to the
specific treatment might have been biased by some
patient characteristics and, since one drug was substan-
tially self-paid and the other one subsidised, the socio-
economic status of the patients could have differed.
However we had no information on subjects’ socio-eco-
nomic status for comparison. On the other hand, the
comparison of subjects’ characteristics found a statisti-
cally significant difference only in the proportion with
liver metastases and the number was higher in the
XELOX group, perhaps increasing the costs in that
group. However, with only 30 subjects in each group,
the statistical power of such comparisons is low and so
we cannot rule out the possibility of some bias in treat-
ment allocation.
Due to the greater number of patients treated on
XELOX than FOLFOX4 in Hong Kong in recent years it
was not possible to match the two chemotherapy groups
in terms of treatment years so some FOLFOX4 patients’
treatments date back to 2004-2005 while all XELOX
patients were 2006-2008. However, we do not believe
that the clinical management practices have changed
much over this time period.
We may have underestimated the benefits of
XELOX. Shiroiwa et al [29] compared the two drug
regimens in Japan using utility values collected during
the clinical trials and estimated quality-adjusted pro-
gression-free survival days. They demonstrated better
q u a l i t yo fl i f ei nt h eX E L O Xg r o u pw h i c ht h e ys a i d
enhanced the regimen’s cost-effectiveness relative to
FOLFOX4.
We had no information on costs of carers and have
therefore underestimated the societal costs but including
these would predictably make XELOX even less costly
than FOLFOX4 because of the time spent attending
hospital by the carer as well as the patient.
Conclusion
We found that using XELOX cost less than using FOL-
FOX4 when all hospital resource use was considered.
The principal reason for this lower cost was the reduced
use of hospital bed-days for the treatment administra-
tion. Taken along with the results of clinical trials, this
would imply that XELOX is a cost-effective option in
Hong Kong. Despite the weaknesses of costing studies,
they can have a role in showing that the impact on
other resources, in this case hospital bed-days and costs
of IV administration, can sometimes more than com-
pensate for higher drug acquisition costs. This may be
particularly important in oncology where tremendous
advances are being made but the purchase price of the
new drugs is often very high.
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